On Feb. 20, BioMarin Pharmaceutical (NASDAQ:BMRN) released fourth-quarter earnings for the period ended Dec. 31.
- Revenues have shot up by 132.4% due to increased revenues from Naglazyme and Aldurazyme.
- The net loss narrowed for the quarter because of better revenues and improvement in margins.
- In January, the company reported positive data for its phase 3 trials of Phenoptin for PKU, a metabolic disease.
- BioMarin announced that the remaining $51.4 million of convertible notes due 2008 was converted into common stock
- The company expects a net loss to the tune of $20 million to $25 million for fiscal 2007, which includes non-cash stock compensation expense of about $16 million to $18 million.
- BioMarin is highly regarded in Motley Fool CAPS, where it sports a four-star rating.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q4 2006 |
Q4 2005 |
Change | |
|---|---|---|---|
|
Sales |
$22.0 |
$9.5 |
132.4% |
|
Net Profit |
($10.4) |
($15.0) |
N/A |
|
EPS |
($0.11) |
($0.20) |
N/A |
|
Diluted Shares |
91.6 |
74.0 |
23.6% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q4 2006 |
Q4 2005 |
Change* | |
|---|---|---|---|
|
Gross Margin |
83.6% |
86.0% |
(2.4) |
|
Operating Margin |
(52.5%) |
(135.4%) |
82.9 |
|
Net Margin |
(47.2%) |
(158.3%) |
111.1 |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$288.8 |
$47.8 |
504.4% |
|
Accounts Rec. |
$14.7 |
$5.9 |
150.3% |
|
Inventory |
$25.1 |
$10.9 |
130.1% |
|
Liabilities |
Q4 2006 |
Q4 2005 |
Change |
|---|---|---|---|
|
Accounts Payable* |
$32.2 |
$20.9 |
53.7% |
|
Long-Term Debt |
$223.9 |
$125.0 |
79.2% |
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows was not provided.
Find out why Fools always follow the money.
Related Foolishness:
Check out our Motley Fool CAPS investor community today. It's fun and free, and could make you a better investor.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
